Posted by Michael Wonder on 03 Sep 2021
Impel NeuroPharma announces U.S. FDA approval of Trudhesa (dihydroergotamine mesylate) nasal spray for the acute treatment of migraine
3 September 2021 - Commercial launch of Trudhesa is planned for early October 2021.
Impel NeuroPharma today announced that the U.S. FDA approved Trudhesa (dihydroergotamine mesylate) nasal spray (0.725 mg per spray) for the acute treatment of migraine with or without aura in adults.
Trudhesa was previously known as INP104.
